Delivery Order SPE2DB22D1017-SPE2DB25FG1AN
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $41,696.62 to AmerisourceBergen Drug Corp for NURTEC ODT 75 MG tablets (8-count units) on August 12, 2025, with an ultimate completion date of August 13, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,304.62 to AmerisourceBergen Drug Corp for NURTEC ODT 75 mg tablets (8-count units) on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed-price delivery order represents a non-competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical support vehicle running through December 2026. The place...
- The Defense Logistics Agency (DLA) awarded a $24,916.23 delivery order to AmerisourceBergen Drug Corp for NURTEC ODT 75 MG tablets (8-count units) on September 15, 2025, with an ultimate completion date of September 16, 2025. This firm fixed price delivery order represents a competitively awarded contract with no set-aside designation. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,373.47 to AmerisourceBergen Drug Corp for NURTEC ODT 75 mg tablets (8-count packages) on September 9, 2025, with a completion date of September 10, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The order will be fulfilled from AmerisourceBergen's location in Conshohocken, Pennsylvania, which serves as the company's corporate headquarters and primary...
- The Defense Logistics Agency (DLA) awarded a $17,326.95 delivery order contract to AmerisourceBergen Drug Corp for NURTEC ODT 75 mg tablets (8-count packages) on August 27, 2025, with completion scheduled for August 28, 2025. This is a firm fixed-price, non-set-aside contract issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $999.999 billion ceiling value through December 2026. AmerisourceBergen, headquartered in...
- The Defense Logistics Agency (DLA) awarded a $23,382.72 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NURTEC ODT 75 mg tablets (8-count units) on September 15, 2025, with completion scheduled for September 16, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was fulfilled...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,193.61 to AmerisourceBergen Drug Corp for NURTEC ODT 75 MG tablets (8-count packaging) with a firm fixed price structure and an ultimate completion date of July 15, 2025. This non-set-aside, competitively awarded contract represents a single delivery order under AmerisourceBergen's larger prime indefinite delivery contract with DLA Troop Support Medical (designated SPE2DX), which is valued at $999,999,999.00 and extends...
- The Defense Logistics Agency awarded a delivery order valued at $89,299.27 to AmerisourceBergen Drug Corp for NURTEC ODT 75 MG tablets (8-count units) on July 18, 2025, with an ultimate completion date of July 21, 2025. The contract is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order valued at $20,329.70 to AmerisourceBergen Drug Corp for NURTEC ODT 75 MG Tablet 8s, a prescription medication used to treat acute migraines. This competitively awarded, firm fixed-price delivery order was issued on August 15, 2025, with an ultimate completion date of August 18, 2025. The contract specifies performance at the contractor's Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate headquarters. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $48,497.72 to AmerisourceBergen Drug Corp for NURTEC ODT 75 mg tablets (8-count packages) on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed-price, competitively awarded contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG1ANDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $22,179.65 to AmerisourceBergen Drug Corp for NURTEC ODT 75 MG tablets (8-count packages) on April 24, 2025, with completion scheduled for April 25, 2025. This is a firm fixed-price, non-set-aside contract with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vehicle designated SPE2DX and running through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical federal medical procurement vendor for military and veteran healthcare systems. The company's extensive portfolio of federal contract awards demonstrates consistent capability to meet DLA requirements through competitive procurement across a wide spectrum of therapeutic domains, including specialty medications, brand-name and generic drugs, vaccines, and medical devices. This particular delivery order for migraine treatment medication supports the DLA's ongoing pharmaceutical supply chain operations serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through the flexible SPE2DX contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.2k | 4/24/25 |